Innovative pharmacological treatment for presbyopia: Benozzi’s method

Session Details

Session Title: Corneal Presbyopia & Astigmatism Correction

Session Date/Time: Tuesday 17/09/2019 | 16:30-18:00

Paper Time: 16:42

Venue: Free Paper Forum: Podium 3

First Author: : G.Benozzi ARGENTINA

Co Author(s): :    J. Leiro   S. Facal   C. Perez   B. Orman                    

Abstract Details

Purpose:

The aim of the present work is to evaluate the efficacy of the binocular pharmacological treatment Método Benozzi, an eye-drop drug combination of a cholinergic agonist and a non-steroidal anti-inflammatory drug.

Setting:

Centro de Investigación Avanzada de la Presbicia, Buenos Aires, Argentina.

Methods:

Prospective study in five hundred (500) emmetropic presbyopic patients (1000 eyes), between 45 and 55 years old, without other ocular pathologies were recruited and evaluated before and after pharmacological treatment Método Benozzi, and 1 year follow up. Assessment included: distance and near visual acuity, near and far refraction, defocus curve, biomicroscopy, intraocular pressure, fundoscopy and side effects. Examination was performed prior to the administration of the eye-drops and then 1-hour, 1-week, 1-month and 1-year post-administration in each eye and binocularly.

Results:

500 presbyopic patients received the eye-drops drug combination: age average 51,7 years old, measurements were taken previously, 1-hour, 1-week, 1-month and 1-year post-administration in each eye and binocularly. Overall results were: 95% of the patients improved the near uncorrected visual acuity (p: 0.001); any patient suffered deterioration in uncorrected distance visual acuity; accommodation amplitude increased up to 2,10 D; far and near visual acuity achieved remained stable up to 1 year, with the chronic use of the eye-drops. No relevant side effects were observed during the 1 year follow-up.

Conclusions:

These results support the prescription of pharmacological treatment for presbyopia for restoring binocular near and far vision acuity in emmetropic patients.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented